Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourSymmetric Triangle
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns down below $0.92
Key levels
Resistance$4.22
Resistance$3.52
Support$2.85
Support$2.40
Latest news & SEC filings
No headlines in the last 90 days.
Indaptus Therapeutics is a clinical-stage biotechnology company developing an immunotherapy given intravenously to treat cancer and viral infections. Its approach uses weakened, inactivated bacteria that do not cause disease, intended to stimulate both innate and adaptive immune responses. The company's lead candidate, Decoy20, was tested in a Phase 1 trial involving people whose advanced tumors had not responded to approved treatments, including alongside an anti-PD-1 antibody. After a change in control, the company is reviewing strategic options, such as acquiring or investing in an operating business.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for INDP.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG
Fair Value
$1.70
5
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
52%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for INDP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:45:25 | $3.16 | 1,040 | $$3K | BUY |
| 16:51:11 | $3.09 | 1,040 | $$3K | BUY |
| 16:22:34 | $3.06 | 3,888 | $$12K | SELL |
| 20:45:25 | $3.20 | 1,189 | $$4K | MIDPOINT |
| 18:08:44 | $3.23 | 1,750 | $$6K | SELL |
5 dark pool trades shown · $$28K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Indaptus Therapeutics, Inc. (INDP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Indaptus Therapeutics, Inc. (INDP) is at $3.19, up 1.11% (+$0.04) at the Nov 13, 2026 close.
INDP last reported on Aug 13, 2026: EPS -$0.02 vs -$1.57 expected — a beat of 98.7%.
INDP does not currently pay a dividend.
Support: $2.85, $2.40, $2.02. Resistance: $3.52, $4.22, $4.94.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.